While the primary and secondary endpoints of this study aim to evaluate the safety and efficacy of this therapeutic regimen, we will have the unique opportunity to determine if the TIME changes throughout treatment, further delineating how Axl and MerTK can play an immunomodulatory role in HNSCC. The gene discussed is MERTK; the disease is head and neck squamous cell carcinoma.